Adamax (984 Da) is a cognitive & neuro research compound currently in stock directly from a verified Chinese manufacturer. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
Adamax (984 Da) is a synthetic neuropeptide structurally derived from Semax — the ACTH(4-7) heptapeptide analogue (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics, Russian Academy of Sciences. Adamax incorporates an adamantane-containing structural modification into the Semax backbone, yielding a compound with a molecular mass of approximately 984 Daltons. This distinguishes it from the structurally related 1032 Da variant, which carries a different adamantane-derived modification. The adamantane moiety — a bicyclic cage hydrocarbon — is well-established in medicinal chemistry as a pharmacokinetic-enhancing modification: it increases lipophilicity and membrane permeability, improves metabolic stability against enzymatic degradation, and enhances central nervous system (CNS) penetration via the blood-brain barrier.
Adamax's pharmacological profile is mechanistically rooted in the Semax lineage. The parent compound, Semax, is one of the most extensively characterised ACTH(4-7) derivatives in neuroscience research — its primary documented effects include dose-dependent upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) mRNA and protein in hippocampal and cortical tissue, modulation of dopaminergic and serotonergic neurotransmission in limbic regions, and neuroprotective activity in cerebral ischaemia models. The adamantane modification in Adamax is studied for its potential to augment these effects through enhanced CNS bioavailability and prolonged duration of action, while retaining the core neurotrophic and neuromodulatory activity of the parent sequence.
PeptidesFromChina.co supplies Adamax (984 Da) as a lyophilized powder at 10 mg per vial, synthesized to ≥98% purity verified by HPLC and confirmed by mass spectrometry. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. All products are intended for laboratory research use only and are not for human consumption.
| Chemical Class | Synthetic neuropeptide; advanced ACTH(4-7) analogue with adamantane modification |
|---|---|
| Parent Compound | Semax (Met-Glu-His-Phe-Pro-Gly-Pro; ACTH(4-7) heptapeptide derivative) |
| Modification | Adamantane-containing structural motif; characteristic of the 984 Da form (distinct from 1032 Da variant) |
| Developed from | ACTH(4-7) analogue research programme, Institute of Molecular Genetics, Russian Academy of Sciences |
| Molecular Weight | ~984 Da |
| Research Areas | BDNF/NGF upregulation, neuroprotection, dopaminergic and serotonergic modulation, cognitive function, CNS bioavailability research |
| Form | Lyophilized powder |
| Storage | −20°C; protect from light and moisture |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| Adamax (984 Da) | 10 mg | 10 vials | ≥98% | In Stock | $99.00 |
Testing method: HPLC / LC-MS. Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Every batch is tested by the manufacturer for purity and concentration as part of routine quality control, using methods such as HPLC and LC-MS. These results are kept in the manufacturer's internal quality-control records and are not issued as a separate certificate or document.
The BDNF and NGF-upregulating activity established for Semax forms the primary neurotrophic research context for Adamax. In Semax studies, dose-dependent increases in BDNF mRNA (1.4–2.0-fold in hippocampus by RT-PCR) and NGF protein (ELISA) are documented at 25–250 μg/kg in rodents. Adamax, as a structurally enhanced analogue, is investigated for whether the adamantane modification shifts the effective dose range or prolongs the duration of neurotrophic factor induction — outcomes studied by pairing Adamax and Semax in the same in vivo BDNF/NGF measurement protocol. TrkB receptor antagonist (ANA-12) pre-treatment experiments are used to confirm BDNF-dependence of any observed downstream effects on synaptic plasticity, LTP, and behavioural cognitive endpoints.
The adamantane moiety is employed in CNS drug design specifically to enhance BBB permeability via increased lipophilicity and interaction with P-glycoprotein transport mechanisms. Comparative BBB penetration studies pairing Adamax (984 Da) against unmodified Semax use brain-to-plasma ratio measurements (LC-MS/MS of brain homogenate and plasma after matched i.v. and i.p. dosing) to quantify CNS exposure. Metabolic stability assays in plasma and liver microsome fractions characterise the enzymatic resistance conferred by the adamantane group, complementing the in vivo pharmacokinetic data. These studies are relevant to identifying compounds with improved CNS exposure-to-peripheral-dose ratios for neuroprotection and cognitive research applications.
Semax administration in rodent microdialysis studies is associated with increased dopamine turnover (elevated DOPAC/DA and HVA/DA ratios) and serotonin release in frontal cortical regions, without direct receptor agonism at dopaminergic or serotonergic sites — an indirect neuromodulatory mechanism distinct from psychostimulants. Adamax is studied in the same neurotransmitter profiling frameworks: in vivo microdialysis in striatum and prefrontal cortex, receptor binding assays (³H-SCH23390 and ³H-ketanserin displacement for D1 and 5-HT2A sites respectively), and behavioural endpoints sensitive to monoamine function (prepulse inhibition, forced swim test serotonin sensitivity). The adamantane modification's effect on potency and duration in these monoaminergic assays is the primary pharmacological differentiation question versus the parent Semax.
Following the established neuroprotective profile of Semax in transient MCAO and global forebrain ischaemia models, Adamax is investigated in comparable experimental injury protocols. Endpoints include infarct volume quantification (TTC staining), neurological deficit scoring, and immunohistochemical markers of neuronal survival (NeuN, MAP2) and microglial activation state (Iba-1 polarisation). Proposed mechanisms of neuroprotection in this compound class — anti-excitotoxic modulation of NMDA receptor pathways, mitochondrial membrane stabilisation, and suppression of ischaemia-induced inflammatory cytokine release — are assessed using the adamantane analogue to characterise whether the pharmacokinetic improvements translate into a wider therapeutic window or lower effective dose in the injury models.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro, ~814 Da) is the parent ACTH(4-7) heptapeptide with an established neuroprotective and nootropic research profile. Adamax incorporates an adamantane-containing modification that increases the molecular weight to ~984 Da and is studied for enhanced blood-brain barrier penetration and metabolic stability. In practical terms, researchers using Adamax are typically investigating whether the structural modification shifts the effective dose range, extends duration of BDNF/NGF induction, or alters the pharmacokinetic profile relative to Semax — rather than studying a compound with an entirely different mechanism.
Both variants incorporate adamantane-derived structural modifications into the Semax backbone, but they differ in the specific modification — resulting in molecular masses of approximately 984 Da and 1032 Da respectively. The 48 Da mass difference is consistent with a difference in the adamantane-containing substituent (e.g., adamantylacetic acid vs. 1-adamantanecarboxylic acid, or different position of attachment). Research comparing the two variants uses paired in vitro and in vivo protocols to characterise differences in receptor binding, BDNF induction potency, BBB penetration ratios, and metabolic stability — the key pharmacokinetic parameters expected to diverge between the two structural forms.
Adamax (984 Da) is supplied as lyophilized powder at ≥98% purity, verified by HPLC and confirmed by mass spectrometry. Vials contain 10 mg. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. Certificates of Analysis are available on request.
Lyophilized Adamax (984 Da) should be stored at −20°C and protected from light and moisture. Reconstituted solution is stable at 4°C for short-term use (up to 14 days). Repeated freeze-thaw cycles should be avoided to preserve peptide integrity.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.